2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Key Points

• Cardiac implantable electronic devices are critical in managing cardiovascular complications.
• Patients aged 65-74 years and those with chronic myeloid leukaemia face unique cardiac risks.
• Guidelines include advanced cardiac magnetic resonance techniques for better diagnosis and management of cardiac issues in cancer patients. Their implementation may improve patient outcomes during cancer treatment.